29 Apr 2026
Up to 30% of the global adult population lives with metabolic dysfunction-associated steatotic liver disease1 (MASLD), a chronic condition characterized by the accumulation of excess fat in the liver. Without timely intervention, many with MASLD will progress to having metabolic dysfunction-associated steatohepatitis (MASH), which increases the risk of liver cancer and may soon surpass viral hepatitis as a major reason for liver transplantation. MASLD can evolve toward metabolic dysfunction and alcohol-associated liver disease (MetALD) when significant alcohol consumption is combined with underlying metabolic risk factors.